UTOLA: UTerin OLAparib

• Status: Active, not recruiting
• Trial end date: 2024-12-01

Summary

This is a phase IIB, national, randomized, double-blinded, comparative, multi-center study, to assess the efficacy of Olaparib as maintenance after a platinum based chemotherapy in patients with Advanced or metastatic endometrial cancer

• Phase: Phase 2

Details

• Lead Sponsor: ARCAGY/ GINECO GROUP
• Treatments: Olaparib